The UCHAP Team Science proposal titled “Novel RadioTheranostics for High-Risk and Advanced Prostate Cancer” has been positively reviewed and approved for funding by the UCCCC. This proposal is the result of a team of 9 PIs from UChicago and Argonne working jointly since last summer. The long-term objective of the research is to leverage the unique combination of Argonne (Argonne National Laboratory), the only DOE (Department of Energy) radioisotope production site in the Midwest region, and UChicago Cyclotron Facility, reestablished in 2017 and still the only academic cyclotron in Chicago and Illinois, to develop novel targeted radionuclide therapy (TRT) and theranostic applications of uncommon medical radioisotopes, not easily available elsewhere, to advance significantly innovations in early detection and improved treatment of cancer.
The project will receive one year of funding for the amount of $225,000 along with a second year of funding for the same amount upon review. With this new funding, more substantial progress on this pilot project can be achieved.
Congratulations to the team!
